[Press release – not published yet] CureVac fails in pivotal COVID-19 vaccine trial with 47% efficacy.

CureVac Fails in Pivotal COVID-19 Vaccine Trial With 47% Efficacy – AP / Reuters

See also: CureVac’s COVID-19 shot just failed in a large trial, a major setback for the Gates-backed biotech – Insider

Press release: CureVac provides update on phase 2b/3 trial of first-generation COVID-19 vaccine candidate, CVnCoV

Commentary on Twitter (thread – click for more)

https://twitter.com/hildabast/status/1405276204526039041